(Q47293822)

13 January 2018

title

Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma (English)

1 reference

13 January 2018

author

Richard Szydlo

3

1 reference

13 January 2018

author name string

Terpos E

1

1 reference

13 January 2018

Politou M

2

1 reference

13 January 2018

Nadal E

4

1 reference

13 January 2018

Avery S

5

1 reference

13 January 2018

Olavarria E

6

1 reference

13 January 2018

Kanfer E

7

1 reference

13 January 2018

Goldman JM

8

1 reference

13 January 2018

Apperley JF

9

1 reference

13 January 2018

Rahemtulla A

10

1 reference

13 January 2018

publication date

1 August 2004

1 reference

13 January 2018

published in

Leukemia

1 reference

13 January 2018

volume

18

1 reference

13 January 2018

issue

8

1 reference

13 January 2018

page(s)

1420-1426

1 reference

13 January 2018

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403423

exact match

0 references

cites work

Aetiology of bone disease and the role of bisphosphonates in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403423

Multiple myeloma: evolving genetic events and host interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403423

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403423

Multiple myeloma biology: lessons from the 5TMM models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403423

Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403423

RANK ligand and osteoprotegerin in myeloma bone disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403423

Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403423

Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403423

Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403423

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403423

Significant and persistent loss of bone mineral density in the femoral neck after haematopoietic stem cell transplantation: long‐term follow‐up of a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403423

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403423

New insights into the pathophysiology and management of bone disease in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403423

Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau phase under interferon-alpha treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403423

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403423

Bone marrow stromal damage after chemo/radiotherapy: occurrence, consequences and possibilities of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403423

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403423

The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403423

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403423

How myeloma cells escape bisphosphonate-mediated killing: development of specific resistance with preserved sensitivity to conventional chemotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403423

Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403423

Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403423

7 January 2021

Immunocytochemistry reveals RANKL expression of myeloma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403423

7 January 2021

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403423

7 January 2021

RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403423

7 January 2021

Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403423

7 January 2021

Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403423

7 January 2021

Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403423

7 January 2021

Acute effects of high-dose chemotherapy followed by bone marrow transplantation on serum markers of bone metabolism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403423

7 January 2021

Mechanisms of bone loss following allogeneic and autologous hemopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403423

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2403423

1 reference

13 January 2018

1 reference

13 January 2018